NASDAQ · ISRG
Intuitive Surgical, Inc.
$448.76+$4.58 (+1.03%)
Intuitive Surgical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 25.69% below the high.
Loading market information…
NYSE · RMD · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
ResMed Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.95% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
ResMed Inc.’s forward annual dividend is $2.64 per share, paid quarterly. The forward yield is 1.04% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
ResMed Inc.’s next earnings report is currently expected on Feb 4, 2027, with estimated earnings per share of $3.03. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow ResMed Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Jul 31, 2025 |
| $2.55+3.66% vs estimate |
| $1.35B+1.32% vs estimate |
| Q3 2025 | Apr 23, 2025 | $2.37-0.42% vs estimate | $1.29B+0.28% vs estimate |
|---|
| Q2 2025 | Jan 30, 2025 | $2.43+4.74% vs estimate | $1.28B+1.24% vs estimate |
|---|
THE ANALYST VIEW
35 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 9 contributors · Median target $230.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$448.76+$4.58 (+1.03%)
Intuitive Surgical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 25.69% below the high.
$97.11+$2.33 (+2.46%)
Medtronic Plc’s quoted price sits in the upper half of its reported 52-week range, 8.67% below the high.
$42.69+$0.26 (+0.61%)
Boston Scientific Corporation’s quoted price sits in the lower half of its reported 52-week range, 59.59% below the high.
$76.42+$0.60 (+0.79%)
GE HealthCare Technologies Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.87% below the high.
$27.12+$0.09 (+0.33%)
Koninklijke Philips N.V.’s quoted price sits in the lower half of its reported 52-week range, 18.9% below the high.
NZ$47.63+NZ$0.25 (+0.53%)
Fisher & Paykel Healthcare Corporation Limited’s quoted price sits in the upper half of its reported 52-week range, 4.01% below the high.
SEK 273.40+SEK 1.50 (+0.55%)
Getinge AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.18% below the high.
$141.39+$2.41 (+1.73%)
Teleflex Incorporated’s quoted price sits in the upper half of its reported 52-week range, 2.49% below the high.
